Denosumab (Xgeva®)

Newfoundland & LabradorCommon name: Denosumab
Brand name: Xgeva®


What is Denosumab?


Denosumab is a monoclonal antibody that is used to treat osteoporosis in men diagnosed with prostate cancer. Denosumab works by stopping bone cells (osteoclasts) from breaking down bone structure.


How is Denosumab administered?


Denosumab is administered by subcutaneous injection (under the skin).


What are possible side effects of this treatment?


Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are some side effects experienced by those who received denosumab. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Diarrhea
  • Fatigue
  • Nausea
  • Rash
  • Skin changes
  • Weakness
 

Is Denosumab covered in my province or territory?

Denosumab is covered by provincial drug programs in:
  • British Columbia
  • Manitoba
  • New Brunswick
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
Denosumab is not covered by provincial drug programs in:
  • Alberta
  • Newfoundland & Labrador
  • Northwest Territories
  • Prince Edward Island
  • Yukon
​Unknown if denosumab is covered by provincial drug programs in:
  • ​Nunavut

VICTORY Program – Supportive Care (XGEVA)
Patient Assistance Programs are offered by pharmaceutical companies to provide medications and/or financial assistance to those who cannot afford to pay for their medicine.

Please call 1-888-706-4717 for more information and to see if you qualify for this program.

 
 
Last Reviewed: July 2017

Donate Now!






Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive